Phase I study to follow up on the change of immunogenicity and lesion condition in subjects who have administered in DNA-based therapeutic vaccine
Not Applicable
Active, not recruiting
- Conditions
- Not Applicable
- Registration Number
- KCT0001526
- Lead Sponsor
- Gegexine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- Female
- Target Recruitment
- 9
Inclusion Criteria
1) The subjects who have visited within 48 weeks after final injection of GX-188E
2) Those who voluntarily signed informed consent form
Exclusion Criteria
1)Prior participation in any clinical trial within 30 days prior to the visit 1
2) Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immune response (IFN-? ELISPOT assay)
- Secondary Outcome Measures
Name Time Method the change of histopathological test;the change of cytological test;the change of HPV infection status;Safety profile(vital signs, physical examination, clinical laboratory tests etc.)